Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. - Wikidata - awgldk - TriplyDB

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease.

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease.

http://www.wikidata.org/entity/Q42602615

about

Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors Practical diagnosis and management of dementia due to Alzheimer's disease in the primary care setting: an evidence-based approach The dendritic hypothesis for Alzheimer's disease pathophysiology.Long-Term Cholinesterase Inhibitor Therapy for Alzheimer's Disease: Practical Considerations for the Primary Care Physician Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care.Risk of Long-Term Care Dependence for Dementia Patients is Associated with Type of Physician: An Analysis of German Health Claims Data for the Years 2006 to 2010.Patient death as a censoring event or competing risk event in models of nursing home placement Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.Update on the pharmacological treatment of Alzheimer's disease Drugs for Alzheimer's disease: are they effective?Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease The art of sharing the diagnosis and management of Alzheimer's disease with patients and caregivers: recommendations of an expert consensus panel Treating patients with moderate to severe Alzheimer's disease: implications of recent pharmacologic studies.Methods to improve the detection of mild cognitive impairment Response to cholinesterase inhibitors affects lifespan in Alzheimer's disease.The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France.Guiding principles for the care of older adults with multimorbidity: an approach for clinicians: American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity.Errors in self-reports of health services use: impact on alzheimer disease clinical trial designs.Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease.The safety and tolerability of donepezil in patients with Alzheimer's disease.Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics Donepezil and life expectancy in Alzheimer's disease: a retrospective analysis in the Tajiri Project.Predictors of long-term cognitive outcome in Alzheimer's disease Practical Principles for the Management of Alzheimer's Disease.The Effects of Anti-Dementia and Nootropic Treatments on the Mortality of Patients with Dementia: A Population-Based Cohort Study in Taiwan Improving physician awareness of Alzheimer disease and enhancing recruitment: the Clinician Partners Program.Lifetime expectancy and quality-adjusted life-year in Alzheimer's disease with and without cerebrovascular disease: effects of nursing home replacement and donepezil administration--a retrospective analysis in the Tajiri Project.Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes.Effects of Food and Drug Administration-approved medications for Alzheimer's disease on clinical progression Cholinesterase inhibitors do not alter the length of stay in nursing homes among patients with Alzheimer's disease: a prospective, observational study of factors affecting survival time from admission to death.Alzheimer's disease: the benefits of early treatment.Cholinergic and glutamatergic drugs in Alzheimer's disease therapy.Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors?Use of medications of questionable benefit in advanced dementia.Dementia and its implications for public health.Factors that influence survival in a probable Alzheimer disease cohort.Recognition and treatment of Alzheimer's disease: a case-based review.Management of patients with Alzheimer's disease: pharmacological treatment and quality of life Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.

P2860

Q24646726-C5E2E827-1AD4-4AF7-A418-08174B23F887 Q26997299-D96CC970-DDDB-465F-A310-898E16366685 Q27006895-005BB418-6693-4764-AD2E-94C7F674F5CA Q27687404-7F0F2754-A25B-486E-A231-008D6131C672 Q30433785-46653575-5F36-4CAF-B493-C22823F62339 Q30443975-B531FB5C-7008-4EEC-B1BD-1C48B7E07BBC Q30996681-F6C0C19F-35C7-4B81-BD4E-9CFD4FDB3821 Q33612928-B4BC9BDB-9BA0-4E68-8891-47289DA49B59 Q33662471-A0BE48CE-0E1F-49B7-B9D7-83FC9EFF4A70 Q33836947-F4539786-A0E2-455C-9DB3-9FCFA5DA18B4 Q33865325-08427C15-44B1-43F0-98A4-76868D5B1BE6 Q33867858-64B4FE1E-EF47-44B1-BF57-36D19368997C Q33902284-E44329D0-E24A-463F-9AD4-ED0679769BED Q33928316-CA0648DE-261F-46E2-A9B5-439ECEF64649 Q33933152-4B905FC6-B9BE-46CE-A3F3-1FE4ABCCD521 Q34233759-CFF8A85E-EE05-4614-8983-236CC274AEC4 Q34363448-D48ECE1C-A0C1-499B-8AF0-94E23A8E3916 Q34418562-8AEC1105-6412-4D90-BCC1-13321F1AD102 Q34543773-06623DDD-AC0A-4C6C-9D04-788C8378DB9A Q34549155-CB66F14D-6BBE-4CCA-9682-ECACB265EF67 Q34552035-8098D396-A924-4828-8E0B-A794437501B5 Q34965949-FE2EE803-BDBE-4E26-971B-6CA6989D178D Q35144642-6D058CFA-9852-4224-93D2-2086774749E6 Q35579243-6C69C6BD-5ECB-4C6D-BDB7-A523D748F58A Q35667052-BC1AE3C4-4222-492B-A951-43845028FEA6 Q35670849-33DFC6B6-D6E6-480F-860A-85702CD2135F Q35784071-D9340956-7BAD-4613-A7B5-12F01A12804C Q35834150-EC8FAEC6-2697-4791-BFC8-10D6EBAF7EAD Q35876403-D9C7129A-FAD0-4D64-B17D-060BE7195C19 Q35925880-419E8E1D-C3E1-4917-8049-D502BD051D0A Q36118948-0B87F2A5-13CC-46AE-8539-2739870F2D2D Q36249975-9B870121-1017-498D-863C-6AA82BD3A674 Q36257227-40D3CD33-2188-4F93-9C21-204E7E96B529 Q36302845-DA903991-47ED-4FB4-9B7F-24116B830171 Q36398853-ECBF3328-A63E-4890-BE82-CB3B79A90FF5 Q36422185-8B6F26D5-0A56-4C8C-B7E1-522D1791C71D Q36424811-D67A046F-1AAB-4FA9-89EF-1E4B2F1D7B5C Q36458308-633DC259-D1FE-4792-8BD2-1FF63D5A398F Q36515587-60113BAC-19A1-42A4-916F-0FD872DE106A Q36600204-C53F249C-C65B-42E8-9357-5AD95172367B

P2860

Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease.

http://www.wikidata.org/entity/Q42602615

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Donepezil is associated with d ...... ents with Alzheimer's disease.

@en

Donepezil is associated with d ...... ents with Alzheimer's disease.

@nl

type

label

Donepezil is associated with d ...... ents with Alzheimer's disease.

@en

Donepezil is associated with d ...... ents with Alzheimer's disease.

@nl

prefLabel

Donepezil is associated with d ...... ents with Alzheimer's disease.

@en

Donepezil is associated with d ...... ents with Alzheimer's disease.

@nl

P1433

Q42602615-C53BB1E9-7396-40FA-A1E2-2E3A60ECEF2A

P1476

Q42602615-CB300817-E28A-41DD-9653-792B26C6FE56

P2093

Q42602615-739FBCA9-27A5-441E-A335-8E66E209AC4E

Q42602615-89981398-99F6-4FC3-BD04-29010D78A682

Q42602615-A1706661-FC59-45FA-A9CD-CE64A8DF55E8

Q42602615-AF5A5891-FB9D-413F-816C-99E9B696F2ED

Q42602615-F095D3C9-A652-4ADD-BB6F-A1431845D900

P2860

Q42602615-0CD2E16B-1335-4A32-9E81-843B5418B27B

Q42602615-184818B5-0FBB-444F-AB82-D8B52D8F79A5

Q42602615-26998A41-D820-4BFE-B5C3-0CB6BC609413

Q42602615-30702849-639D-4BD2-9AEB-EED631608497

Q42602615-328F75CC-98E8-4E55-89F2-D2B8A6CEE697

Q42602615-44D51F93-AA75-47A7-96D4-261922EC1182

Q42602615-B3ACC046-31D2-47F7-953A-F2F1BEA185FD

Q42602615-DD1FD756-492B-4DAB-8653-A48DD7795E91

Q42602615-E95BA4C2-E729-47B8-9B9C-196E055E6D8A

Q42602615-F286DD56-412A-4304-AFC1-6C5FEFBCA650

P304

Q42602615-51A9C7EE-5B40-4FE1-8DFC-B5C2CEE5659B

P31

Q42602615-63741E1C-1AFE-439A-B583-5AE39C52B6F5

P356

Q42602615-4EDCD753-29DA-47E6-90F3-62EF642DC270

P407

Q42602615-704B7AC1-5511-4B68-B1EB-CADEF1FF1B01

P433

Q42602615-CBCA6B32-5ECE-4F59-9734-4FD26EC2D328

P478

Q42602615-6BD1DC24-0F66-4080-98ED-11F6AE91FD22

P577

Q42602615-96F335AB-F85C-40F1-A441-3C06B586A614

P698

Q42602615-D0CA124F-8A5D-4073-AF84-6B2EB905B1F9

P921

Q42602615-C957BD30-224B-42B1-934B-481D44761C0A

P356

J.1365-2389.2003.51306.X

P1433

Journal of the American Geriatrics Society

P1476

Donepezil is associated with d ...... ents with Alzheimer's disease.

@en

P2093

David S Geldmacher

http://www.w3.org/2001/XMLSchema#string

George Provenzano

http://www.w3.org/2001/XMLSchema#string

John R Ieni

http://www.w3.org/2001/XMLSchema#string

Thomas McRae

http://www.w3.org/2001/XMLSchema#string

Vera Mastey

http://www.w3.org/2001/XMLSchema#string

P2860

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group.

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part XI. Clinical milestones in patients with Alzheimer's disease followed over 3 years.

Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease.

Factors determining the decision to institutionalize dementing individuals: a prospective study.

Longitudinal study of death and institutionalization in patients with primary degenerative dementia.

Dementia: the experience of family caregivers.

P304

937-944

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2389.2003.51306.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12834513

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease